{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:44:04Z","timestamp":1794408244554,"version":"4.9.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2021A1515010093"],"award-info":[{"award-number":["2021A1515010093"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023A1515011862"],"award-info":[{"award-number":["2023A1515011862"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700148"],"award-info":[{"award-number":["81700148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.leukres.2024.107622","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T10:05:20Z","timestamp":1731146720000},"page":"107622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["RCHOP plus BTK inhibitor improves clinical outcomes in double expressor diffuse large B-cell lymphoma, unlike RCHOP plus lenalidomide"],"prefix":"10.1016","volume":"148","author":[{"given":"Demei","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenrui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.leukres.2024.107622_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2024.107622_bib2","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/s41409-023-02006-3","article-title":"Clinical relevance of MYC\/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant","volume":"58","author":"Al-Juhaishi","year":"2023","journal-title":"Bone Marrow Transpl."},{"issue":"28","key":"10.1016\/j.leukres.2024.107622_bib3","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.leukres.2024.107622_bib4","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2024.107622_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00403-009-0967-1","article-title":"Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin\u2019s lymphoma","volume":"301","author":"Colovic","year":"2009","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.leukres.2024.107622_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102443","article-title":"Treatment strategies for patients with diffuse large B-cell lymphoma","volume":"110","author":"Poletto","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.leukres.2024.107622_bib7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1586\/14737140.6.8.1175","article-title":"Rituximab for the treatment of diffuse large B-cell lymphomas","volume":"6","author":"Held","year":"2006","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"11","key":"10.1016\/j.leukres.2024.107622_bib8","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"12","key":"10.1016\/j.leukres.2024.107622_bib9","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2024.107622_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.blre.2016.09.004","article-title":"High grade B-cell lymphoma with rearrangements of MYC and BCL2 and\/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma","volume":"31","author":"Rosenthal","year":"2017","journal-title":"Blood Rev."},{"issue":"4","key":"10.1016\/j.leukres.2024.107622_bib11","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41375-018-0320-9","article-title":"Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma","volume":"33","author":"Dodero","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107622_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1219167","article-title":"Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement","volume":"14","author":"Geng","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2024.107622_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J. Hematol. Oncol."},{"issue":"25","key":"10.1016\/j.leukres.2024.107622_bib14","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107622_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"3","key":"10.1016\/j.leukres.2024.107622_bib16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.beha.2018.08.001","article-title":"Optimizing initial therapy in DLBCL","volume":"31","author":"Thieblemont","year":"2018","journal-title":"Best. Pract. Res Clin. Haematol."},{"issue":"7","key":"10.1016\/j.leukres.2024.107622_bib17","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","article-title":"Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial","volume":"15","author":"Vitolo","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2024.107622_bib18","unstructured":"Nowakowski G.S., LaPlant B., Macon W.R., et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2015;33(3):251-257. doi:Hartert KT, Wenzl K, Krull JE, et al: Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL. Leukemia 10.1038\/s41375-020-0766-4 [epub ahead of print on March 5, 2020]."},{"issue":"15","key":"10.1016\/j.leukres.2024.107622_bib19","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.leukres.2024.107622_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.leukres.2024.107622_bib21","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.leukres.2024.107622_bib22","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.leukres.2024.107622_bib23","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107622_bib24","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.20.01375","article-title":"Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107622_bib25","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2024.107622_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7005","article-title":"A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88mut \/CD79Bmut diffuse large B-cell lymphoma","volume":"13","author":"Deng","year":"2024","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.leukres.2024.107622_bib27","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1182\/bloodadvances.2022009389","article-title":"Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.leukres.2024.107622_bib28","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3324\/haematol.2021.278638","article-title":"Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome","volume":"107","author":"Dodero","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.leukres.2024.107622_bib29","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol."},{"issue":"9880","key":"10.1016\/j.leukres.2024.107622_bib30","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"issue":"5 Suppl 14","key":"10.1016\/j.leukres.2024.107622_bib31","first-page":"88","article-title":"CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma","volume":"26","author":"Czuczman","year":"1999","journal-title":"Semin Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107622_bib32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1365-2141.1999.01129.x","article-title":"The difference in NK-cell activity between patients with non-Hodgkin\u2019s lymphomas and Hodgkin\u2019s disease","volume":"104","author":"Konjevi\u0107","year":"1999","journal-title":"Br. J. Haematol."},{"issue":"28","key":"10.1016\/j.leukres.2024.107622_bib33","doi-asserted-by":"crossref","first-page":"23769","DOI":"10.1074\/jbc.M112.372425","article-title":"Tyrosine kinase Btk is required for NK cell activation","volume":"287","author":"Bao","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2024.107622_bib34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.omto.2021.03.015","article-title":"Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma","volume":"21","author":"Yu","year":"2021","journal-title":"Mol. Ther. Oncolytics"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T15:01:00Z","timestamp":1736780460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624001887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":34,"alternative-id":["S0145212624001887"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107622","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RCHOP plus BTK inhibitor improves clinical outcomes in double expressor diffuse large B-cell lymphoma, unlike RCHOP plus lenalidomide","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107622"}}